Retatrutide Research Hub

Retatrutide is a synthetic 39-amino-acid triple agonist of the GLP-1, GIP, and glucagon receptors (CAS 2381089-83-2, about 4731 Da). It is studied in research on metabolism, energy expenditure, and lipid handling.

Semaglutide activates the GLP-1 receptor. Tirzepatide activates the GLP-1 and GIP receptors. Retatrutide adds activity at the glucagon receptor, which is the basis of research into energy expenditure and hepatic lipid and glucose handling that the other two do not address in the same way.

Research areas include energy expenditure, lipid metabolism, and hepatic glucose handling, alongside comparative incretin-pathway studies against single and dual agonists. The literature is expanding quickly, and results should be read against the specific model and assay conditions used.

QSC supplies 5, 10, 15, 20, 30, 40, 50, 60, 80, 100 and 120 mg vials. Choose by stock concentration and how quickly you will use the solution: a 10 mg vial in 2 mL gives 5 mg/mL, and a 100 mg vial in 10 mL gives 10 mg/mL. Check the vial capacity before adding solvent.

Reconstitution at 5 to 10 mg/mL in sterile water is most commonly cited. Because its triple-receptor profile is sensitive to assay conditions, confirm your protocol before bulk procurement. Keep lyophilized powder at -20°C for long-term storage and refrigerate after reconstitution.

Prices are per 10-vial pack of one size. Email us to arrange a smaller order at the same per-vial price. Orders of $1,000 or more ship free, and delivery is typically about 10 to 15 days, duties paid.

It is a pre-mixed 1:1 research blend of retatrutide and tirzepatide, 30 mg of each per vial (60 mg total), for protocols that use both compounds together and prefer one reconstitution step.

The research-grade material QSC supplies is not approved for human or veterinary use and is sold strictly for laboratory research. Nothing on this site is medical advice.